Analysts Offer Predictions for FSD Pharma Inc.’s Q1 2024 Earnings (NASDAQ:HUGE)

Posted by Defense World Staff on May 9th, 2024

FSD Pharma Inc. (NASDAQ:HUGE – Free Report) – Stock analysts at Singular Research issued their Q1 2024 earnings per share estimates for FSD Pharma in a report released on Tuesday, May 7th. Singular Research analyst B. Cook forecasts that the company will post earnings of ($0.05) per share for the quarter. Singular Research currently has a “Buy-Venture” rating on the stock. Singular Research also issued estimates for FSD Pharma’s Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.12) EPS.

FSD Pharma (NASDAQ:HUGE – Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.04) earnings per share (EPS) for the quarter.

FSD Pharma Stock Down 4.3 %

Shares of HUGE opened at $0.35 on Thursday. The company has a market cap of $13.97 million, a P/E ratio of -0.74 and a beta of 0.71. FSD Pharma has a fifty-two week low of $0.34 and a fifty-two week high of $1.68. The firm’s 50 day moving average price is $0.63 and its 200 day moving average price is $0.86.

Institutional Trading of FSD Pharma

A hedge fund recently raised its stake in FSD Pharma stock. AdvisorShares Investments LLC lifted its stake in FSD Pharma Inc. (NASDAQ:HUGE – Free Report) by 14.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 270,316 shares of the company’s stock after purchasing an additional 34,679 shares during the period. AdvisorShares Investments LLC owned about 0.69% of FSD Pharma worth $249,000 at the end of the most recent quarter. 1.24% of the stock is currently owned by hedge funds and other institutional investors.

About FSD Pharma

(Get Free Report)

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.